Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy

Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy

Redx Pharma Plc is pleased to confirm that its lead cancer treatment, the Porcupine inhibitor (RXC004), has a potential role in cancer immunotherapy. Redx scientists have demonstrated that the Porcupine inhibitor could have a crucial role in improving the immune system response of some cancer patients when used in combination with an existing immunotherapy, anti-programmed cell death-1 (anti-PD-1).

Anti-PD-1 therapy activates the immune system to recognise and attack tumours. While treatment with PD-1 inhibitors, also known as Checkpoint inhibitors, is a significant breakthrough in cancer treatment, not all patients respond.

Redx has been testing a combination therapy that uses both the Porcupine inhibitor RXC004 and an anti-PD-1 antibody in a cancer model. The data demonstrates that the combination therapy significantly improves the ratio of favourable T-cells, which attack tumours, to the immunosuppressive T-cells that allow tumours to grow unrecognised, when compared to only using an anti-PD-1 therapy. This suggests that a combination therapy could potentially improve patient response rates.

Redx’s novel, potent small molecule Porcupine inhibitor has already shown, in disease models, that it has potential as a stand-alone therapy for difficult to treat cancers, such as pancreatic cancer.

As previously reported, first-in-human studies for the Porcupine inhibitor, initially as a stand-alone therapy, are expected to commence early in 2017. In addition, Redx is now evaluating opportunities for combination therapies.

Neil Murray, CEO of Redx, commented: The results so far from our Porcupine inhibitor, RXC004, have been very impressive, with important implications for difficult to treat cancers, such as pancreatic cancer.

Over the past few years, significant progress has been made in harnessing the ability of the immune system to attack cancer. We are very pleased that our new findings confirm that our lead cancer treatment, the Porcupine inhibitor RXC004, now also has a potentially crucial role in enhancing existing cancer immunotherapy treatments.

Our Porcupine program has progressed from concept to moving towards first-in-human clinical trials in a little under three years, which is a remarkable achievement and evidence of our commercially disciplined approach and outstanding scientific capabilities.”

Read more at RedxPharma.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.